BioSpace News Archive

Arcturus Therapeutics Holdings Inc. announced that the Company will participate in the following investor conferences.

Napo Pharmaceuticals (Napo), a Jaguar Health, Inc. (NASDAQ:JAGX) family company, today announced that the last patient has completed their final visit for the stage 1 primary endpoint treatment period of Napo’s pivotal Phase 3 OnTarget trial of crofelemer for preventive treatment of diarrhea in adult cancer patients with solid tumors receiving targeted therapy with or without standard chemotherapy.

NeurAxis, Inc., a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, announced it has generated over $8 million in revenue following the commercial launch of its proprietary IB-Stim™ technology.

Neurophth Therapeutics, Inc. (“Neurophth”) announced today that the first patient has been dosed in the international multi-region, multi-center Phase I/II clinical trial for the treatment of Leber hereditary optic neuropathy caused by ND1 mutation (ND1-LHON).

Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced the publication of a post-hoc analysis of the pivotal, Phase 3 study (MCI186-19) reviewing the effect of intravenous (IV) RADICAVA® (edaravone) on survival and additional disease progression milestone events in people with amyotrophic lateral sclerosis (ALS).

Quanta Dialysis Technologies® today announced that it has completed enrollment of its Home Run study for at-home hemodialysis.

Biocytogen Pharmaceuticals Co., Ltd. announced that its Project Integrum has completed 2 core milestones, and its antibody business is now entering a new stage of rapid growth.

Marker Therapeutics (NASDAQ: MRKR) highlights its technology during a recently held, 75-minute Demi-Colton Virtual Salon/Webinar on cell therapy and CAR-T, a breakthrough cancer treatment that modifies a patient’s own T cells to fight cancer.

US Digestive Health, one of the largest gastroenterology practices in the United States, announced the opening of its new office location with additional providers, further expanding its footprint in Bucks County, Pennsylvania.

The global precision oncology market size is estimated to grow from USD 1,00,060 million in 2022 to reach around USD 2,58,350 million by 2032, growing at a CAGR of 9.9% from 2023 to 2032, A study published by Towards Healthcare.